Cargando…
Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects
Among many applications of therapeutic monoclonal antibodies (mAbs), a unique approach for regenerative medicine has entailed antibody-mediated osseous regeneration (AMOR). In an effort to identify a clinically relevant model of craniofacial defect, the present study investigated the efficacy of mAb...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851338/ https://www.ncbi.nlm.nih.gov/pubmed/29682573 http://dx.doi.org/10.1155/2018/9508721 |
_version_ | 1783306376826585088 |
---|---|
author | Khojasteh, A. Hosseinpour, S. Dehghan, M. M. Mashhadiabbas, F. Rezai Rad, M. Ansari, S. Farzad Mohajeri, S. Zadeh, H. H. |
author_facet | Khojasteh, A. Hosseinpour, S. Dehghan, M. M. Mashhadiabbas, F. Rezai Rad, M. Ansari, S. Farzad Mohajeri, S. Zadeh, H. H. |
author_sort | Khojasteh, A. |
collection | PubMed |
description | Among many applications of therapeutic monoclonal antibodies (mAbs), a unique approach for regenerative medicine has entailed antibody-mediated osseous regeneration (AMOR). In an effort to identify a clinically relevant model of craniofacial defect, the present study investigated the efficacy of mAb specific for bone morphogenetic protein- (BMP-) 2 to repair canine segmental mandibular continuity defect model. Accordingly, a 15 mm unilateral segmental defect was created in mandible and fixated with a titanium plate. Anorganic bovine bone mineral with 10% collagen (ABBM-C) was functionalized with 25 μg/mL of either chimeric anti-BMP-2 mAb or isotype-matched mAb (negative control). Recombinant human (rh) BMP-2 served as positive control. Morphometric analyses were performed on computed tomography (CT) and histologic images. Bone densities within healed defect sites at 12 weeks after surgery were 1360.81 ± 10.52 Hounsfield Unit (HU), 1044.27 ± 141.16 HU, and 839.45 ± 179.41 HU, in sites with implanted anti-BMP-2 mAb, rhBMP-2, and isotype mAb groups, respectively. Osteoid bone formation in anti-BMP-2 mAb (42.99% ± 8.67) and rhBMP-2 (48.97% ± 2.96) groups was not significantly different but was higher (p < 0.05) than in sites with isotype control mAb (26.8% ± 5.35). In view of the long-term objective of translational application of AMOR in humans, the results of the present study demonstrated the feasibility of AMOR in a large clinically relevant animal model. |
format | Online Article Text |
id | pubmed-5851338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58513382018-04-22 Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects Khojasteh, A. Hosseinpour, S. Dehghan, M. M. Mashhadiabbas, F. Rezai Rad, M. Ansari, S. Farzad Mohajeri, S. Zadeh, H. H. Biomed Res Int Research Article Among many applications of therapeutic monoclonal antibodies (mAbs), a unique approach for regenerative medicine has entailed antibody-mediated osseous regeneration (AMOR). In an effort to identify a clinically relevant model of craniofacial defect, the present study investigated the efficacy of mAb specific for bone morphogenetic protein- (BMP-) 2 to repair canine segmental mandibular continuity defect model. Accordingly, a 15 mm unilateral segmental defect was created in mandible and fixated with a titanium plate. Anorganic bovine bone mineral with 10% collagen (ABBM-C) was functionalized with 25 μg/mL of either chimeric anti-BMP-2 mAb or isotype-matched mAb (negative control). Recombinant human (rh) BMP-2 served as positive control. Morphometric analyses were performed on computed tomography (CT) and histologic images. Bone densities within healed defect sites at 12 weeks after surgery were 1360.81 ± 10.52 Hounsfield Unit (HU), 1044.27 ± 141.16 HU, and 839.45 ± 179.41 HU, in sites with implanted anti-BMP-2 mAb, rhBMP-2, and isotype mAb groups, respectively. Osteoid bone formation in anti-BMP-2 mAb (42.99% ± 8.67) and rhBMP-2 (48.97% ± 2.96) groups was not significantly different but was higher (p < 0.05) than in sites with isotype control mAb (26.8% ± 5.35). In view of the long-term objective of translational application of AMOR in humans, the results of the present study demonstrated the feasibility of AMOR in a large clinically relevant animal model. Hindawi 2018-02-28 /pmc/articles/PMC5851338/ /pubmed/29682573 http://dx.doi.org/10.1155/2018/9508721 Text en Copyright © 2018 A. Khojasteh et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Khojasteh, A. Hosseinpour, S. Dehghan, M. M. Mashhadiabbas, F. Rezai Rad, M. Ansari, S. Farzad Mohajeri, S. Zadeh, H. H. Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title | Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title_full | Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title_fullStr | Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title_full_unstemmed | Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title_short | Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects |
title_sort | antibody-mediated osseous regeneration for bone tissue engineering in canine segmental defects |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851338/ https://www.ncbi.nlm.nih.gov/pubmed/29682573 http://dx.doi.org/10.1155/2018/9508721 |
work_keys_str_mv | AT khojasteha antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT hosseinpours antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT dehghanmm antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT mashhadiabbasf antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT rezairadm antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT ansaris antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT farzadmohajeris antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects AT zadehhh antibodymediatedosseousregenerationforbonetissueengineeringincaninesegmentaldefects |